Blueprint Medicines Corp BPMC

NAS: BPMC | ISIN: US09627Y1091   10/05/2024
106,70 USD (-1,51%)
(-1,51%)   10/05/2024

6 mei 2024 · Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

2 mei 2024 · Blueprint Medicines Reports Strong First Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance · Persbericht

18 april 2024 · Blueprint Medicines to Report First Quarter 2024 Financial Results on Thursday, May 2, 2024 · Persbericht

11 april 2024 · Blueprint Medicines to Host Webcast and Conference Call Highlighting Emerging Opportunities for Mast Cell-Targeted Therapeutics · Persbericht

4 april 2024 · Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

6 maart 2024 · Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

23 februari 2024 · Blueprint Medicines Highlights AYVAKIT® (avapritinib) Long-Term Efficacy and Safety Data and Advances in Mast Cell Disease Research at 2024 AAAAI Annual Meeting · Persbericht

15 februari 2024 · Blueprint Medicines Reports Fourth Quarter and Full Year 2023 Results · Persbericht

5 februari 2024 · Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

1 februari 2024 · Blueprint Medicines to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, February 15, 2024 · Persbericht

8 januari 2024 · Blueprint Medicines Highlights 2024 Corporate Strategy and Business Priorities at 42nd Annual J.P. Morgan Healthcare Conference · Persbericht

5 januari 2024 · Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

18 december 2023 · Blueprint Medicines to Present at 42nd Annual J.P. Morgan Healthcare Conference · Persbericht

12 december 2023 · Blueprint Medicines' AYVAKYT® (avapritinib) Receives European Commission Approval as the First and Only Treatment for Indolent Systemic Mastocytosis · Persbericht

9 december 2023 · Blueprint Medicines' Leadership in Driving Continued Innovation in Systemic Mastocytosis Highlighted at 2023 ASH Annual Meeting · Persbericht

4 december 2023 · Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

10 november 2023 · Blueprint Medicines' AYVAKYT® (avapritinib) Receives Positive CHMP Opinion as the First and Only Therapy for Indolent Systemic Mastocytosis · Persbericht

3 november 2023 · Blueprint Medicines Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

26 oktober 2023 · Blueprint Medicines Reports Third Quarter 2023 Results · Persbericht

23 oktober 2023 · Anixa Biosciences Appoints Accomplished Medical Oncologist and Biotechnology Executive, Dr. Mark A. Goldberg, to Cancer Business Advisory Board · Persbericht

Mijn selecties